icon-folder.gif   Conference Reports for NATAP  
  17th European AIDS Conference
November 6-9
2019, Basel
Back grey_arrow_rt.gif
Dolutegravir-based regimens are associated with weight gain over two years following ART-initiation in ART-na´ve people living with HIV (PLWH)
  17th European AIDS Conference, November 6-9, 2019, Basel
Reported by Jules Levin
SA Ruderman1, RM Nance1, BM Whitney1, JAC Delaney1, BN Harding1, KH Mayer2, RD Moore3, JJ Eron4, E Geng5, WC Mathews6, B Rodriguez7, MS Saag8, S Lindstr÷m1, BR Wood1, AC Collier1, V Vannappagari9, C Henegar9, J Van Wyk10, L Curtis11, GA Burkholder8, MM Kitahata1, HM Crane1
1University of Washington; 2Harvard Medical School, Fenway Institute; 3Johns Hopkins; 4University of North Carolina, Chapel Hill; 5University of California San Francisco; 6University of California San Diego;
7Case Western University; 8University of Alabama at Birmingham; 9ViiV Healthcare, RTP, NC, USA; 10ViiV Healthcare, Brentford, UK; 11GlaxoSmithKline, Uxbridge, UK





* TAF regimens not included as mean follow up time is shorter due to more recent approval